Journal article icon

Journal article

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.

Abstract:

Systemic amyloidosis is a fatal disorder caused by pathological extracellular deposits of amyloid fibrils that are always coated with the normal plasma protein, serum amyloid P component (SAP). The small-molecule drug, miridesap, [(R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC)] depletes circulating SAP but leaves some SAP in amyloid deposits. This residual SAP is a specific target for dezamizumab, a fully humanized monoclonal IgG1 anti-SAP antibo...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Sub department:
Botnar Research Centre
Oxford college:
St Hilda's College
Role:
Author
ORCID:
0000-0002-8093-7084
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDM
Sub department:
Tropical Medicine
Role:
Author
Expand authors...
Publisher:
American Association for the Advancement of Science Publisher's website
Journal:
Science Translational Medicine Journal website
Volume:
10
Issue:
422
Article number:
eaan3128
Publication date:
2018-01-03
Acceptance date:
2017-09-26
DOI:
EISSN:
1946-6242
ISSN:
1946-6234
Pmid:
29298867
Source identifiers:
1033401
Language:
English
Keywords:
Pubs id:
pubs:1033401
UUID:
uuid:adf41c20-48b6-4020-b8bc-f0de6f3ec82a
Local pid:
pubs:1033401
Deposit date:
2019-07-18

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP